Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
Kizzmekia S. Corbett, Martha Nason, Britta Flach, et al.
Science (2021) Vol. 373, Iss. 6561
Open Access | Times Cited: 298

Showing 1-25 of 298 citing articles:

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Peter B. Gilbert, David C. Montefiori, Adrian B. McDermott, et al.
Science (2022) Vol. 375, Iss. 6576, pp. 43-50
Open Access | Times Cited: 1020
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 817-838
Open Access | Times Cited: 939
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Markus Hoffmann, Nadine Krüger, Sebastian Schulz, et al.
Cell (2021) Vol. 185, Iss. 3, pp. 447-456.e11
Open Access | Times Cited: 869
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2127-2135
Open Access | Times Cited: 533
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair Munro, Leila Janani, Victoria Cornelius, et al.
The Lancet (2021) Vol. 398, Iss. 10318, pp. 2258-2276
Open Access | Times Cited: 429
Covid-19 Vaccines — Immunity, Variants, Boosters
Dan H. Barouch
New England Journal of Medicine (2022) Vol. 387, Iss. 11, pp. 1011-1020
Open Access | Times Cited: 378
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
Jiří Zahradník, Shir Marciano, Maya Shemesh, et al.
Nature Microbiology (2021) Vol. 6, Iss. 9, pp. 1188-1198
Open Access | Times Cited: 377
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients
Lu Lu, Bobo Wing-Yee Mok, Lin Lei Chen, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e822-e826
Open Access | Times Cited: 373
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
Franz X. Heinz, Karin Stiasny
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 339
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
Matthew McCallum, Alexandra C. Walls, Kaitlin R. Sprouse, et al.
Science (2021) Vol. 374, Iss. 6575, pp. 1621-1626
Open Access | Times Cited: 285
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans
Philip A. Mudd, Anastasia A. Minervina, Mikhail V. Pogorelyy, et al.
Cell (2021) Vol. 185, Iss. 4, pp. 603-613.e15
Open Access | Times Cited: 251
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
David Goldblatt, Galit Alter, Shane Crotty, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 6-26
Open Access | Times Cited: 233
Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines
Alessandro Sette, Shane Crotty
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 27-46
Open Access | Times Cited: 214
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
Matthew Gagné, Juan I. Moliva, Kathryn E. Foulds, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1556-1571.e18
Open Access | Times Cited: 210
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
Alexandra C. Walls, Kaitlin R. Sprouse, John E. Bowen, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 872-880.e3
Open Access | Times Cited: 197
COVID-19 vaccination: The road ahead
Daniel M. Altmann, Rosemary J. Boyton
Science (2022) Vol. 375, Iss. 6585, pp. 1127-1132
Closed Access | Times Cited: 180
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
John E. Bowen, Amin Addetia, Ha V. Dang, et al.
Science (2022) Vol. 377, Iss. 6608, pp. 890-894
Open Access | Times Cited: 174
Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity
Lauren B. Rodda, Peter A. Morawski, Kurt B. Pruner, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1588-1601.e14
Open Access | Times Cited: 171
Defining the risk of SARS-CoV-2 variants on immune protection
Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, et al.
Nature (2022) Vol. 605, Iss. 7911, pp. 640-652
Open Access | Times Cited: 152
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Chris Ka Pun Mok, Carolyn A. Cohen, Samuel M. S. Cheng, et al.
Respirology (2021) Vol. 27, Iss. 4, pp. 301-310
Open Access | Times Cited: 149
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
Peter B. Gilbert, David C. Montefiori, Adrian B. McDermott, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 128
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Ali Zhang, Hannah D. Stacey, Michael R. D’Agostino, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 6, pp. 381-396
Open Access | Times Cited: 126
Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
Lu Lu, Bobo Wing-Yee Mok, Lin‐Lei Chen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 123
Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
Vivek Naranbhai, Wilfredo F. García-Beltrán, Christina C. Chang, et al.
The Journal of Infectious Diseases (2021) Vol. 225, Iss. 7, pp. 1141-1150
Open Access | Times Cited: 118
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 117
Page 1 - Next Page

Scroll to top